Clinical Trial Update: Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tocladesine for recurrent or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Tocladesine

Snippet

Sponsor: Northwestern University | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED